| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Nanomedicine | - | ||
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Nanomedicine | - | ||
Preclinical data readout example | Pre-clinical | — | Subscribe to access the data. | Nanomedicine | - |
Recent Updates
Recently added Catalysts
Aerovate Therapeutics, Inc.$93.8
+0.7 (+0.75%)
Market Cap
77.68 M
EPS
-1.70
P/E Ratio
-
Value Trade
2.77 M
-2.9 %
Week
5.1 %
1 Month
5.1 %
3 Month
19.11 %
6 Month
-90.43 %
5 Year
-90.43 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
29.37 K
52 Week Range
1.25 - 32.42
% held by Insiders
14.37 %
% held by Institutions
79.32 %
Enterprise Value
-17.45 M
Total Shares
28.98 M
Short %
14.44 %
Float Shares
11.85 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AV-101 | Pulmonary Arterial Hypertension | Phase 1 | 2022-05-16 | generally well tolerated; significantly reduced systemic exposure compared with oral imatinib; no serious adverse events reported; most common TEAEs were dizziness and headache; most common TEAEs in MAD were short periods of cough and headache, primarily in the 90 mg cohort Read More | Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) Read More | |
AV-101 | Pulmonary Arterial Hypertension | Phase 1 | 2022-05-16 | generally well tolerated; significantly reduced systemic exposure compared with oral imatinib; no serious adverse events reported; most common TEAEs were dizziness and headache; most common TEAEs in MAD were short periods of cough and headache, primarily in the 90 mg cohort Read More | Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) Read More | |
AV-101 | Pulmonary Arterial Hypertension | Phase 1 | 2022-05-16 | generally well tolerated; significantly reduced systemic exposure compared with oral imatinib; no serious adverse events reported; most common TEAEs were dizziness and headache; most common TEAEs in MAD were short periods of cough and headache, primarily in the 90 mg cohort Read More | Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVTE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVTE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How AVTE ranks across every disease it competes inCompetitive Position is a premium feature
See how AVTE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial